Bridged Peptide Analogue of RA-VII, an Antitumor Bicyclic Hexapeptide
Synlett · 24.01.2023 · 34 (02) · 183-187
DOI: 10.1055/a-1960-4340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synlett, erschienen am 24.01.2023. Verfasst von Yukio Hitotsuyanagi und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
A bridged peptide analogue of RA-VII was designed, in which the α carbons of residues 1 and 4 were linked by a tetramethylene chain to restrict the conformational freedom of the backbone of the 18-membered cyclopeptide. This peptide analogue was synthesized by a ring-closing metathesis reaction of [l-2-allylglycine-1, l-2-allylglycine-4]RA-VII and a subsequent hydrogenation of the resulting olefinic compound. Compared with RA-VII, the analogue showed much weaker cytotoxic activity toward human promyelocytic leukemia HL-60 cells and human colon carcinoma HCT-116 cells, which may be accounted for by the difference in the orientation of the Tyr-6 phenyl ring plane between the analogue and RA-VII.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Hitotsuyanagi, Y., Hinosawa, T., Nakagawa, Y., Ito, S., Lee, J., & Hasuda, T. (2023). Bridged Peptide Analogue of RA-VII, an Antitumor Bicyclic Hexapeptide. Synlett, 34(02), 183-187. https://doi.org/10.1055/a-1960-4340
Vancouver
Hitotsuyanagi Y, Hinosawa T, Nakagawa Y, Ito S, Lee J, Hasuda T. Bridged Peptide Analogue of RA-VII, an Antitumor Bicyclic Hexapeptide. Synlett. 2023;34(02):183-187. doi:10.1055/a-1960-4340
BibTeX
@article{Hitotsuyanagi2023,
author = {Hitotsuyanagi, Yukio and Hinosawa, Taka-aki and Nakagawa, Yoshie and Ito, Sho and Lee, Ji-Ean and Hasuda, Tomoyo},
title = {Bridged Peptide Analogue of RA-VII, an Antitumor Bicyclic Hexapeptide},
journal = {Synlett},
year = {2023},
volume = {34},
number = {02},
pages = {183--187},
doi = {10.1055/a-1960-4340}
}
EUVIMED